Analysts at Bank Hapoalim reiterate their Buy recommendation for
(Nasdaq:TEVA) and state a share target price of $74. Teva closed Monday at a price of $57.75.
Analyst Rakefet Levison stresses the splendid financial results that Teva released for fourth quarter 2000 and for the year. She says that the several positive developments of 2000 and the expected developments of the coming year support continued positive financial outcome.
Levison estimates that Teva's 2001 income will reach $2.057 billion, 18% more than in 2000. She estimates that 2002 sales will grow to $2.295 billion.
Levinson writes that investing in Teva provides an attractive mix of strength, in the generic pharmaceutical market and the multiple sclerosis market, with rapid growth, a strong management team, and advanced research and development capabilities.